|
Nogapendekin Alfa Inbakicept
Nogapendekin alfa inbakicept, sold under the brand name Anktiva, is a fixed-dose combination medication used for the treatment of bladder cancer. It is an interleukin-15 receptor agonist. It is given in combination with Bacillus Calmette-Guérin via intravesical drug delivery. It contains nogapendekin alfa, a human IL-15N72D variant; and inbakicept, an interleukin 15 receptor subunit alpha. The most common adverse reactions include increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills, and pyrexia. Nogapendekin alfa inbakicept was approved for medical use in the United States in April 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. Medical uses Nogapendekin alfa inbakicept is indicated with Bacillus Calmette-Guérin for adults with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Interleukin-15 Receptor
Interleukin-15 receptor is a type I cytokine receptor, binding interleukin-15. Structure The IL-15 receptor is composed of the IL-2Rβ and γc subunits, along with a unique ligand-specific subunit, IL-15Rα, which bears homology to IL-2Rα. These receptor proteins feature protein-binding motifs known as "sushi domains." In both humans and mice, these receptors and their corresponding ligands are physically linked in the genome. Due to their shared receptor usage, IL-2 and IL-15 exhibit many similarities in their effects on lymphoid cells. Although the receptors for IL-2 and IL-15 share many structural analogies, two significant differences persist: Firstly, IL-15Rα has a broader expression compared to IL-2Rα, IL-2Rβ, and γc. It is found on lymphoid cells, dendritic cells (DCs), fibroblasts, epithelial cells, liver cells, intestinal cells and other cells and is thought to present IL-15 in trans to cells expressing IL-15β and γ chains. Secondly, IL-15Rα exhibits a ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Intravesical Drug Delivery
Intravesical drug delivery is the drug delivery, delivery of medications directly into the bladder by urinary catheter. This method of drug delivery is used to directly target diseases of the bladder such as interstitial cystitis and bladder cancer, but currently faces obstacles such as low drug retention time due to washing out with urine and issues with the low permeability of the bladder wall itself. Due to the advantages of directly targeting the bladder, as well as the effectiveness of penetration enhancers, permeability enhancers, advances in intravesical drug carriers, and mucoadhesion, mucoadhesive, intravesical drug delivery is becoming more effective and of increased interest in the medical community. Advantages Delivering drugs directly to the target bladder site allows for maximizing drug delivery while minimizing systemic effects. Delivering the treatment directly to the site allows for more effective dosages to be given since high concentrations of drug in the bl ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
